PARKING REQUEST FORM » | MAP & DIRECTIONS » |
|
ARB 304
|
ARB 305
|
ARB 354
|
ARB 355
|
Links to Teams Meeting
|
||||
SESSION 1
1:00 – 1:45
|
Julie Hubbard, Pharm.D.
Management of Immunosuppression After Kidney Transplant Graft Failure
|
Erin Houry, Pharm.D.
Efficacy and Safety of Valproic Acid for ICU Agitation/Delirium
|
Kelsey Olion, Pharm.D.
Aspirin for Primary Prevention of Cardiovascular Events
|
Kelly Knauer, Pharm.D.
The Role of Pharmacogenomic Testing in Therapy Selection for Major Depressive Disorder
|
1:45 – 1:55 pm
|
Travel Time to accommodate movement between rooms
|
|||
SESSION 2
1:55 – 2:40
|
Alison Croft, Pharm.D.
A New Strategy to Manage Chemotherapy-Induced Neutropenia
|
Sarah Singer, Pharm.D.
Sedation in the ICU--Where Do We Stand?
|
Reed Smith, Pharm.D.
The Role of SGLT2 Inhibitors in Heart Failure
|
Kevin Wegener, Pharm.D.
Use of Granulocyte Colony-Stimulating Factors in Decompensated Cirrhosis.
|
2:40 – 2:50 pm
|
Travel Time to accommodate movement between rooms
|
|||
SESSION 3
2:50 – 3:40
|
Caroline Patz, Pharm.D.
Antifungal Prophylaxis in Pediatric Lung Transplants
|
Robert Montealegre, Pharm.D.
Prothrombin Complex Concentrate in the Trauma Patient: Is Protein the Missing Factor?
|
Rebecca Fong, Pharm.D.
Role of Bacteriostatic Agents in Gram-positive Bloodstream Infections
|
Madison Wilmes, Pharm.D.
Tenecteplase vs. Alteplase for Acute Ischemic Stroke
|
Registration is free but is required in advance for the LIVE presentations. Due to limited space, only those participants who register for the LIVE session before 5:00 PM on Friday, October 8, 2021 will be able to request parking access on campus.
PARKING: To request parking, please first register for your desired LIVE sessions. Then, complete the Parking Request Form using the link above, or complete your parking request by clicking here>>>. If you do not request parking on our campus, or if you do not submit your request by the deadline, you will be re-directed upon arrival.
ATTENDANCE: All live participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against completed evaluations. Attendance for the virtual sessions will be captured once a participant joins the session and will be reconciled with completed evaluations. Any sessions that you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT: Immediately following Resident Seminar, participants should complete an evaluation for EACH presentation attended (3 maximum) by clicking here>>>. Participants will have one week after attending the session to complete the evaluation. The CPE Administrator will submit each participant’s NABP number and date of birth combination to CPE Monitor for continuing education credit, no later than two weeks after the live and virtual presentations. Only ONE session may be claimed for each of the three blocks. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign or the attendance roster within Microsoft Teams Meeting, the offending participant forfeits CE credit.
SPECIAL ACCOMMODATIONS
Attendees of all abilities are welcome to participate. If you require reasonable accommodations, please notify Nicole Fields via email at Nicole.Fields@uhsp.edu in advance so that she may secure resources as soon as possible. Every effort will be made to make accommodations where necessary.
Date: Oct 13, 2021 01:00 PM - 03:40 PM
Fee
CE Hours
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists
Accreditation(s)
St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. To learn more about the specific program information, including universal activity numbers (UAN's) and learning objectives, please expand the modules below. Following successful completion of an evaluation, CE credit will be automatically reported to NABP through the CPE Monitor system, using the NABP ePID numbers and date of birth (MMDD) stored in participants' user profiles. Follow this link to learn more about CPE Monitor and the credit reporting process » Participants are responsible for ensuring receipt of credit; no credit can be corrected or awarded if more than 60 days have passed from the date of the event or if the home study is expired.
It is the policy of St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating in this program are expected to disclose to the program audience any real or apparent conflicts of interest related to the content of the presentation.
|
Objectives
- Identify risk factors associated with kidney allograft failure
- Determine appropriate immunosuppression management for those who develop allograft failure after kidney transplant
- Identify risks and benefits of continuing immunosuppression in patients with failed kidney allografts
Speaker(s)/Author(s)
Julie Hubbard, Pharm.D. |
Activity Number
0033-0000-21-036-L01-PCE Hours
Location
Objectives
- Identify risk factors for ICU delirium.
- Describe the mechanism of action of valproic acid in ICU agitation/delirium.
- Select patients who are candidates for valproic acid for ICU agitation/delirium.
Speaker(s)/Author(s)
Erin Houry, Pharm.D. |
Activity Number
0033-0000-21-035-L01-PCE Hours
Location
Objectives
- Describe the mechanism of action of aspirin as it relates to primary prevention.
- Determine appropriateness of low-dose aspirin for primary prevention in specific patients based on evidence available from primary literature.
- Identify aspirin's place in therapy based on the available clinical practice guidelines.
Speaker(s)/Author(s)
Kelsey Olion, Pharm.D. |
Activity Number
0033-0000-21-040-L01-PCE Hours
Location
Objectives
- Select an appropriate antidepressant therapy based on a pharmacogenomics report
- Identify key conclusions from the GUIDED trial outcomes
- Distinguish patients that may benefit from the use of pharmacogenomic testing
Speaker(s)/Author(s)
Kelly Knauer, Pharm.D. |
Activity Number
0033-0000-21-045-L01-PCE Hours
Location
Objectives
- Identify risk factors for developing chemotherapy-induced neutropenia
- Distinguish risks of trilaciclib versus current standard of care
- Select indication(s) for the use of trilaciclib
Speaker(s)/Author(s)
Alison Croft, Pharm.D. |
Activity Number
0033-0000-21-044-L01-PCE Hours
Location
Objectives
- Appraise the outcomes from recent sedation literature and how it has impacted clinical practice over the years.
- Examine key limitations of the recent MENDS2 trial.
Speaker(s)/Author(s)
Sarah Singer, Pharm.D. |
Activity Number
0033-0000-21-041-L01-PCE Hours
Location
Objectives
- Explain the mechanism of action of SGLT2 inhibitors in diabetes and the proposed mechanisms of actions in heart failure
- Describe the current literature looking at the use of SGLT2 inhibitors in heart failure
- Identify heart failure populations who would benefit from an SGLT2 inhibitor
Speaker(s)/Author(s)
Reed Smith, Pharm.D. |
Activity Number
0033-0000-21-042-L01-PCE Hours
Location
Objectives
- Summarize proposed mechanisms of benefit of G-CSFs in decompensated cirrhosis.
- Predict when G-CSF therapy may be beneficial based on patient characteristics.
- Describe G-CSF dosing regimens used for decompensated cirrhosis.
Speaker(s)/Author(s)
Kevin Wegener, Pharm.D. |
Activity Number
0033-0000-21-046-L01-PCE Hours
Location
Objectives
- Describe the medication regimens commonly utilized for antifungal prophylaxis in pediatric lung transplant patients, including guideline recommendations
- Explain the risks related to the use of voriconazole as post-transplant antifungal prophylaxis in lung transplant patients
Speaker(s)/Author(s)
Caroline Patz, Pharm.D. |
Activity Number
0033-0000-21-037-L01-PCE Hours
Location
Objectives
- Identify the mechanism of trauma-induced coagulopathy (TIC)
- Describe the risks and benefits of using factor replacement in a patient with trauma-induced coagulopathy
Speaker(s)/Author(s)
Roberto Montealegre, Pharm.D. |
Activity Number
0033-0000-21-038-L01-PCE Hours
Location
Objectives
- Distinguish between traditional and microbiological terms “bactericidal” and “bacteriostatic”
- Describe specific patient populations and scenarios that can feasibly be treated with bacteriostatic agents for bloodstream infections
- Identify appropriate antibiotic treatment regimens based on available primary literature
Speaker(s)/Author(s)
Rebecca Fong, Pharm.D. |
Activity Number
0033-0000-21-039-L01-PCE Hours
Location
Objectives
- Describe differences between fibrinolytic therapies, alteplase and tenecteplase
- Identify the results of published clinical trials comparing their use in acute ischemic stroke
- List advantages of tenecteplase and alteplase
Speaker(s)/Author(s)
Madison Wilmes, Pharm.D. |